Biomarin Pharmaceutical (BMRN) Leases (2019 - 2024)
Historic Leases for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Q4 2024 value amounting to $28.7 million.
- Biomarin Pharmaceutical's Leases fell 3288.25% to $28.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $28.7 million, marking a year-over-year decrease of 3288.25%. This contributed to the annual value of $28.7 million for FY2024, which is 3288.25% down from last year.
- Biomarin Pharmaceutical's Leases amounted to $28.7 million in Q4 2024, which was down 3288.25% from $42.7 million recorded in Q4 2023.
- Over the past 5 years, Biomarin Pharmaceutical's Leases peaked at $49.1 million during Q1 2020, and registered a low of $28.7 million during Q4 2024.
- For the 5-year period, Biomarin Pharmaceutical's Leases averaged around $41.6 million, with its median value being $44.2 million (2020).
- As far as peak fluctuations go, Biomarin Pharmaceutical's Leases soared by 2231.57% in 2023, and later crashed by 3288.25% in 2024.
- Over the past 5 years, Biomarin Pharmaceutical's Leases (Quarter) stood at $46.0 million in 2020, then fell by 16.99% to $38.2 million in 2021, then decreased by 8.54% to $34.9 million in 2022, then grew by 22.32% to $42.7 million in 2023, then crashed by 32.88% to $28.7 million in 2024.
- Its last three reported values are $28.7 million in Q4 2024, $42.7 million for Q4 2023, and $34.9 million during Q4 2022.